Kyverna Therapeutics to Present at Upcoming Investor Conferences

Kyverna Therapeutics (KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases, announced upcoming presentations at the H.C. Wainwright 4th Annual Nasdaq BioConnect Conference on May 19th and the Jefferies Global Healthcare Conference on June 3rd, 2026. The company is advancing its lead CAR T-cell therapy candidate miv-cel across multiple B-cell-driven autoimmune indications, including stiff person syndrome and generalized myasthenia gravis.

05/14/2026, 8:00 AM • GlobeNewswire

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Kyverna Therapeutics announced positive primary analysis results from its KYSA-8 registrational trial of miv-cel (mivocabtagene autoleucel) for stiff person syndrome (SPS). A single dose demonstrated statistically significant improvements across all primary and secondary endpoints at 16 weeks, with 81% of patients achieving clinically meaningful improvement in walking speed and all 26 patients discontinuing chronic immunotherapies. The company plans to submit a BLA for this indication and is advancing the therapy in generalized myasthenia gravis.

04/21/2026, 6:45 PM • GlobeNewswire

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

Kyverna Therapeutics announced the appointments of Sravan K. Emany and Andrew Miller to its Board of Directors as the company advances toward commercialization of its cell therapies for autoimmune diseases. Emany, currently CFO of Beam Therapeutics, brings capital markets and rare disease expertise, while Miller, a Time Magazine honoree and former Karuna Therapeutics leader, adds clinical development and product approval experience. Dan Spiegelman has stepped down from the Board.

02/24/2026, 8:00 AM • GlobeNewswire

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T therapies. Looking ahead to 2026, analysts expect continued M&A activity and strategic partnerships, though risks remain including FDA staff turnover and an 'IPO air pocket' from the 2023-2024 downturn.

12/31/2025, 10:01 AM • Benzinga

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Kyverna Therapeutics, a clinical-stage biopharmaceutical company, has priced a public offering of 13,333,333 shares at $7.50 per share, expecting to raise approximately $100 million to support its cell therapy development for autoimmune diseases.

12/17/2025, 9:24 AM • Benzinga

Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate Clarity

U.S. stock markets experienced a slight decline on December 15, 2025, with the S&P 500, Nasdaq, and Dow Jones showing modest losses as investors await economic data and potential Federal Reserve rate decisions.

12/15/2025, 6:20 PM • The Motley Fool

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Kyverna Therapeutics will host a conference call to discuss topline results from its Phase 2 clinical trial of KYV-101, a CD19 CAR T-cell therapy targeting stiff person syndrome, with potential for durable disease-free remission.

12/14/2025, 2:30 PM • GlobeNewswire

Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight

The diffuse cutaneous systemic sclerosis (dcSSc) market is evolving towards targeted therapies addressing fibrosis and immune modulation, with promising drug candidates from multiple pharmaceutical companies targeting various pathogenic pathways.

10/06/2025, 1:00 PM • GlobeNewswire

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Kyverna Therapeutics announced details of its Phase 3 clinical trial for KYV-101, a potential first-in-class CAR T-cell therapy targeting myasthenia gravis and stiff person syndrome, with plans to initiate patient enrollment by year-end 2025.

08/28/2025, 8:00 AM • GlobeNewswire